These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
612 related articles for article (PubMed ID: 32135579)
1. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Ladikou EE; Chevassut T; Pepper CJ; Pepper AG Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579 [TBL] [Abstract][Full Text] [Related]
2. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317 [TBL] [Abstract][Full Text] [Related]
3. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia]. Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448 [TBL] [Abstract][Full Text] [Related]
4. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Peled A; Tavor S Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784 [TBL] [Abstract][Full Text] [Related]
5. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077 [TBL] [Abstract][Full Text] [Related]
6. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Tavor S; Petit I Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871 [TBL] [Abstract][Full Text] [Related]
7. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis. Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086 [TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Scupoli MT; Donadelli M; Cioffi F; Rossi M; Perbellini O; Malpeli G; Corbioli S; Vinante F; Krampera M; Palmieri M; Scarpa A; Ariola C; Foà R; Pizzolo G Haematologica; 2008 Apr; 93(4):524-32. PubMed ID: 18322253 [TBL] [Abstract][Full Text] [Related]
9. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Cho BS; Kim HJ; Konopleva M Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003 [TBL] [Abstract][Full Text] [Related]
10. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398 [TBL] [Abstract][Full Text] [Related]
11. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Sison EA; McIntyre E; Magoon D; Brown P Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844 [TBL] [Abstract][Full Text] [Related]
12. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566 [TBL] [Abstract][Full Text] [Related]
13. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment. Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122 [TBL] [Abstract][Full Text] [Related]
14. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging. Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351 [TBL] [Abstract][Full Text] [Related]
15. Targeting the microenvironment in acute myeloid leukemia. Rashidi A; Uy GL Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388 [TBL] [Abstract][Full Text] [Related]
16. Role of CXCR4 in the progression and therapy of acute leukaemia. Su L; Hu Z; Yang YG Cell Prolif; 2021 Jul; 54(7):e13076. PubMed ID: 34050566 [TBL] [Abstract][Full Text] [Related]
17. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446 [TBL] [Abstract][Full Text] [Related]
18. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. Saglio G; Fava C Leuk Lymphoma; 2009 Oct; 50(10):1564-5. PubMed ID: 19757319 [No Abstract] [Full Text] [Related]
20. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]